Investor Update: Dr. Reddy's Laboratories Ltd.

Regulatory Update: Mexico API Facility Dr. Reddy's Laboratories announced the conclusion of a USFDA records assessment at its active pharmaceutical ingredient (API) manufacturing facility in Jiutepec, Mexico (Industrias Químicas Falcón de México). Conducted between July 17 and September 8, 2026, under Section 704(a)(4) of the FD&C Act, the assessment resulted in a Form FDA 2953 citing two observations. Management has affirmed its commitment to compliance and will submit a comprehensive response within the stipulated regulatory timeline. Q1 Financial Performance Overview This regulatory development follows a challenging first quarter, characterized by unforeseen provisions and broader macroeconomic headwinds: Net Profit: ₹443.5 crore (a 69% YoY decline, trailing consensus estimates of ₹817.8 crore). Topline Revenue: ₹8,070.5 crore (a 6% YoY decrease, missing expectations of ₹8,804.7 crore). EBITDA: ₹1,009 crore (down 55% YoY). EBITDA margins contracted to 12.5% from 26.7% in the year-ago period. Primary Margin Headwinds The Q1 earnings miss was largely driven by a one-off ₹240 crore provision related to the company's semaglutide API business. Furthermore, operating margins faced downward pressure from elevated freight and solvent costs stemming from the ongoing geopolitical conflict in West Asia. Operational Pipeline & Regional Performance North American revenues (27% of consolidated total) fell 35% YoY to ₹2,200 crore, primarily due to normalized Lenalidomide sales. However, the region demonstrated short-term resilience with a 26% sequential QoQ growth. Market Reaction Despite the recent earnings miss and regulatory observations, the stock has shown near-term stability. Shares of Dr. Reddy's recently closed up 1.77% at ₹1,161.00 on the BSE, as the market digests the company's remediation strategies and pipeline potential.